

New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

Matteo Bassetti, MD, PhD^{1,2} Alessandra Mularoni, MD, PhD³ Daniele Roberto Giacobbe, MD, PhD^{1,2}
Nadia Castaldo, MD^{4,5} Antonio Vena, MD, PhD^{1,2}

¹Infectious Diseases Unit, San Martino Policlinico Hospital—IRCCS for Oncology and Neurosciences, Genoa, Italy

²Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

³Department of Infectious Diseases, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IRCCS), Palermo, Italy

⁴Division of Infectious Diseases, Department of Medicine, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

⁵Department of Pulmonology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy

Address for correspondence Matteo Bassetti, MD, PhD, Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, Genova, Largo R. Benzi 10, Genova, 16132, Italy
(e-mail: matteo.bassetti@hsanmartino.it).

Antonio Vena, MD, PhD, Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, Genova, Largo R. Benzi 10, Genova, 16132, Italy (e-mail: anton.vena@gmail.com).

Semin Respir Crit Care Med 2022;43:280–294.

Abstract

Keywords

- ▶ HAP
- ▶ VAP
- ▶ nosocomial pneumonia
- ▶ new antibiotics
- ▶ multidrug resistant
- ▶ *Pseudomonas aeruginosa*
- ▶ *Klebsiella pneumoniae*

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent one of the most common hospital-acquired infections, carrying a significant morbidity and risk of mortality. Increasing antibiotic resistance among the common bacterial pathogens associated with HAP and VAP, especially *Enterobacterales* and nonfermenting gram-negative bacteria, has made the choice of empiric treatment of these infections increasingly challenging. Moreover, failure of initial empiric therapy to cover the causative agents associated with HAP and VAP has been associated with worse clinical outcomes. This review provides an overview of antibiotics newly approved or in development for the treatment of HAP and VAP. The approved antibiotics include ceftobiprole, ceftolozane–tazobactam, ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, and cefiderocol. Their major advantages include their high activity against multidrug-resistant gram-negative pathogens.

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are some of the most common and serious infections occurring in hospitalized patients.^{1–3} The mortality rate for HAP and VAP ranges between 20 and 50%^{4,5} and can reach 75% in some specific settings or when lung infection is caused by multidrug-resistant (MDR) pathogens.^{1,6,7}

Because several studies have shown that appropriate initial antibiotic therapy for patients with HAP and VAP significantly improves outcome, an adequate selection of initial treatments represents crucial clinical goals.^{1,8–10} However, rates of resistance to “old antibiotics” frequently used to treat HAP and VAP are on the rise,^{11,12} and a growing

proportion of pathogens isolated from patients with nosocomial pneumonia now display multidrug resistance.^{13,14} Evidence suggests that infections caused by MDR pathogens have worse clinical prognosis because of a delay in initiating adequate antibiotic treatment.^{15,16}

Reflecting these observations, several novel agents have been developed in recent years to supplement the paucity of agents available for the treatment of MDR pathogens and many of these new antibiotics have been trialed in HAP and VAP (▶ **Table 1**). This review covers those agents that have reached at least phase 2 or 3 trials or have been recently licensed for the treatment of HAP or VAP.

Issue Theme HAP and VAP after Guidelines; Guest Editors: Ignacio Martin-Loeches, MD, and Antoni Torres, MD

© 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0041-1740605>.
ISSN 1069-3424.

Table 1 New molecules FDA and EMA approved for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia

| Drug | Spectrum | Labeled indications | Approved dosage for the treatment of HAP/VAP |
|--------------------------------|---|--|--|
| Ceftobiprole | Nonextended spectrum β -lactamase, non-AmpC and non-carbapenemases-producing <i>Enterobacterales</i> , <i>P. aeruginosa</i> , MRSA | EMA: HAP excluding VAP, CAP, ABSSSI | 500 mg every 8 h by IV infusion over 2 h |
| Ceftazidime-avibactam | ESBL, KPC, AmpC, and some OXA (e.g., OXA 48) producing <i>Enterobacterales</i> , MDR <i>P. aeruginosa</i> , MDR <i>A. baumannii</i> | FDA: HAP/VAP, cUTIs, cIAIs EMA: all those infections due to aerobic gram-negative organisms with limited treatment options | 2 g of ceftazidime and 0.5 g of avibactam every 8 h by IV infusion over 2 h |
| Ceftolozane-tazobactam | ESBL-producing <i>Enterobacterales</i> , MDR <i>P. aeruginosa</i> , some anaerobes, <i>Streptococcus</i> spp., MSSA | FDA: HAP/VAP, cUTIs, cIAIs EMA: HAP/VAP, cUTIs, cIAIs | 2 g of ceftolozane and 1 g of tazobactam every 8 h by IV infusion over 1 h |
| Meropenem-vaborbactam | ESBL, KPC, AmpC-producing <i>Enterobacterales</i> , non-MDR <i>P. aeruginosa</i> , non-MDR <i>A. baumannii</i> , <i>Streptococcus</i> spp. MSSA | FDA: cUTI, including pyelonephritis. EMA: cUTI (including pyelonephritis), HAP, VAP, cIAI, and infections due to aerobic GNB with limited treatment options | 2 g of meropenem and 2 g of vaborbactam every 8 h by IV infusion over 3 h |
| Imipenem-relebactam cilastatin | ESBL, KPC-producing <i>Enterobacterales</i> , MDR <i>P. aeruginosa</i> , <i>Streptococcus</i> spp., MSSA | FDA: HAP/VAP, cIAI, cUTI; EMA: infections due to aerobic GNB with limited or no other therapeutic options | 500 mg of imipenem; 500 mg of cilastatin, and 250 mg of relebactam administered by IV infusion every 6 h over 30 min |
| Cefiderocol | ESBL, CRE (class A, B, and D enzymes), CR <i>P. aeruginosa</i> , <i>S. maltophilia</i> , <i>A. baumannii</i> , <i>Streptococcus</i> spp. | FDA: cUTI, HAP/VAP EMA: infections due to aerobic GNB with limited therapeutic options | 2 g every 8 h by IV infusion over 3 h |

Abbreviations: ABSSSI, acute bacterial skin and skin structure infections; cIAI, complicated intra-abdominal infection; CRE, carbapenem-resistant *Enterobacterales*; cUTI, complicated urinary tract infection; EMA, European Medicines Agency; ESBLs, extended-spectrum β -lactamases; FDA, Food And Drug Administration; GNB, gram-negative bacteria; HAP, hospital-acquired pneumonia; IV, intravenous; MBL, metallo- β lactamase; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *Staphylococcus aureus*; OXA, oxacillinase; VAP, ventilator-associated pneumonia.

Approved Antibiotics for the Treatment of HAP and VAP

Ceftobiprole

Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of HAP, excluding VAP.¹⁷ Ceftobiprole has a broad-spectrum antibacterial activity, including methicillin-resistant *Staphylococcus aureus* (MRSA), *Moraxella catarrhalis*, *Haemophilus influenzae*, penicillin-resistant pneumococci (PRP), the majority of nonextended spectrum β -lactamase, non-AmpC and non-carbapenemases-producing *Enterobacterales*, and *Pseudomonas aeruginosa*. Ceftobiprole is degraded by extended spectrum β -lactamase (ESBL) and by carbapenemase and is not active against gram-negative anaerobes, *Acinetobacter baumannii*, *Burkholderia cepacia*,

Stenotrophomonas maltophilia, *Proteus vulgaris*, and *Enterococcus faecium*.^{17–21} Ceftobiprole exerts its time-dependent antibacterial activity by binding to different penicillin-binding proteins including PBP2a, making ceftobiprole the only β -lactam (together with ceftaroline) active against MRSA and PBP2x of PRP.^{19,22} Ceftobiprole is poorly bound to plasma proteins, has minimal propensity for drug–drug interactions, has a short half-life, and is excreted by the renal filter.¹⁷ Dose adjustment is recommended in patients with moderate to severe kidney failure while it is not necessary in patients with severe obesity.²³ When creatinine clearance (CrCl) is greater than 150 mL/min, extending infusion time to 4 hours is required to keep plasma levels above the minimum inhibitory concentration (MIC).^{24,25} Ceftobiprole has demonstrated a good safety profile, and the most common

adverse events (AEs) with ceftobiprole include headache, nausea, diarrhea, vomiting, infusion-site reactions, dysgeusia, and drug-related hypersensitivity.²⁶ In a 2010 study, no measurable concentrations of ceftobiprole were detected in feces following intravenous (IV) administration in healthy volunteers and no *Clostridioides difficile* strains or toxins were found.²⁷ A phase 3 noninferiority, double-blind, multicenter, international, randomized study in 781 hospitalized patients has demonstrated safety and efficacy of ceftobiprole^{28,29} (500 mg/8 hour infused in 2 hours) versus ceftazidime (2 g/8 hour) plus linezolid (600 mg/12 hour) for the treatment of HAP and VAP. Treatment duration was 7 to a maximum of 14 days. The primary efficacy endpoint was clinical cure at the test-of-cure (TOC) visit, defined as resolution of signs and symptoms of infection, or improvement to such an extent that no further antimicrobial therapy was necessary, in the intent-to-treat (ITT) and clinically evaluable (CE) populations. Ceftobiprole monotherapy was noninferior to comparator arm for patients with HAP. In the VAP group, the study failed to demonstrate noninferiority, possibly due to insufficient sample size; higher heterogeneity in VAP patients according to demographic, clinical, and microbiological characteristics; and to the suboptimal concentration achieved at infection site in critically ill patients in which higher dosage and prolonged infusion might be required.^{17,24} In conclusion, due to its safety profile and in vitro activity against most commonly associated HAP pathogens ceftobiprole may be a valuable therapeutic for HAP with the benefit of a monotherapy regimen.

Ceftolozane-Tazobactam

Ceftolozane-tazobactam is a combination of a novel semi-synthetic fifth-generation cephalosporin with a well-established β -lactamase inhibitor. Ceftolozane overcomes the most common mechanisms of bacterial resistance including hydrolysis by AmpC β -lactamases³⁰ and changes in efflux pumps or porin permeability.^{31,32} The addition of tazobactam to ceftolozane, in a 2:1 ratio, expands its activity against β -lactamases-producing *Enterobacterales*, including those strains producing ESBLs.³³ However, the combination of ceftolozane-tazobactam is not active against Ambler Class A, B, or D carbapenemases.³⁴

As for in vitro studies, ceftolozane-tazobactam exhibits enhanced activity against *P. aeruginosa*, being especially active against MDR or extremely drug-resistant (XDR) strains,³⁵ including those strains resistant to carbapenems.³² The MIC of ceftolozane-tazobactam against *P. aeruginosa* is 8- to 16-fold lower than that of ceftazidime, imipenem, or ciprofloxacin.³⁶ In a recent surveillance study performed in the United States, the susceptibility of *P. aeruginosa* isolates was higher for ceftolozane-tazobactam (97.3%) in comparison to cefepime (86.3%), ceftazidime (85.2%), meropenem, or piperacillin-tazobactam (80.9% each).^{37,38} In this study, the only comparator with higher activity than ceftolozane-tazobactam against *P. aeruginosa* was colistin (99.5% susceptible).

Although its efficacy seems to be variable depending on the species, ceftolozane-tazobactam also shows great activity against ESBL-producing *Enterobacterales* (84–94%),^{37,39–41}

with lower rates of susceptibility reported for ESBL-producing *Klebsiella pneumoniae* (57%) or *Enterobacter cloacae* (64%).^{42–44} As for anaerobes, gram-positive cocci, *Acinetobacter* spp., and *Stenotrophomonas maltophilia*,^{32,42} the activity of ceftolozane-tazobactam is limited.

Regarding pharmacokinetic, ceftolozane-tazobactam penetrates well in the lung tissue as suggested by studies performed in healthy subject receiving 1 g of ceftolozane and 0.5 g of tazobactam. This study showed an Epithelial Lining Fluid (ELF)/plasma area under the curve (AUC) ratio of 0.48, thus indicating that ELF concentrations of ceftolozane-tazobactam may potentially exceed the MICs of most gram-negative pathogens causing nosocomial pneumonia.⁴⁵ However, to ensure therapeutic drug concentration at the site of the infection and to cover pathogen with higher MICs, the drug is currently approved for the treatment of HAP and VAP at the dosage of 2 g of ceftolozane with 1 g of tazobactam every 8 hours.⁴⁶ Since both ceftolozane and tazobactam are primarily eliminated through renal excretion, dosage adjustment is required for patients with acute or chronic kidney injury.⁴⁷

The approval of ceftolozane-tazobactam for the treatment of nosocomial pneumonia was based on the ASPECT-NP study, a noninferiority phase 3 trial comparing the efficacy and safety of ceftolozane-tazobactam 3 g every 8 hours with meropenem 1 g every 8 hours for 7 to 14 days of therapy. The primary efficacy was assessed based on all-cause mortality at day 28. Overall, of the 726 randomized patients, 519 (71%) had VAP. Most patients were in the ICU, and half of them had septic shock. The majority of the VAP were caused by *K. pneumoniae*, *Escherichia coli*, and *P. aeruginosa*.

Ceftolozane-tazobactam met the prespecified noninferiority criterion based on the 28-day mortality rate (24.0% in the ceftolozane-tazobactam group and 25.3% in the meropenem group; weighted proportional difference: 1.1% [95% confidence interval (CI): -5.1 to 7.4]). Of importance, in patients with ventilated HAP and in those in whom previous antibacterial therapy was unsuccessful before study entry, the 95% CI for the between-group difference did not cross zero, with lower mortality in the ceftolozane-tazobactam group than in the meropenem group.⁴⁸

Regarding experiences coming from daily clinical practice, a recent meta-analysis including 33 real-world studies on respiratory tract infections reported similar outcomes (clinical and microbiological success) with ceftolozane-tazobactam as those observed in pivotal clinical trials. These results were observed despite including a greater proportion of MDR pathogens as well as patients with serious underlying diseases, which may have been excluded from pivotal trials.⁴⁹

A retrospective, multicenter, observational cohort study compared patients treated with ceftolozane-tazobactam with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant *P. aeruginosa* (half of the patients had VAP with 7% of them being bacteremic). Patients receiving ceftolozane-tazobactam had a better clinical cure (adjusted odds ratio [aOR]: 2.63; 95% CI, 1.31–5.30) and lower acute kidney injury (aOR: 0.08; 95% CI: 0.03–0.22).⁵⁰

Promising results have been also obtained in a multicenter Italian cohort study including 101 patients treated with ceftolozane–tazobactam for severe infections caused by *P. aeruginosa*. Overall, 32% of the patients had HAP/VAP, and in 61% of the cases the drug was administered as second-line therapy because of failure or previous antimicrobial therapy. Overall, clinical success was observed in 84 of 101 patients (83.2%) at the end of the treatment. Regarding the subgroup of nosocomial pneumonia, the clinical success rate was 75%.⁵¹ Bassetti et al also provided real-world clinical data regarding the role of ceftolozane–tazobactam in the treatment of 153 patients with ESBL-producing *Enterobacteriales*.⁵² Almost half (48.3%) of the patients were admitted to the ICU at the time of their infection and 30.0% of them had HAP or VAP. Pathogens most commonly included were *E. coli* and *K. pneumoniae*. Clinical success was observed in 78.3% of the patients, whereas 30-day mortality was reported for 9.8% of them. In multivariate analysis, receiving ceftolozane–tazobactam as empiric therapy (OR, 0.12; 95% CI, 0.01–0.34; $p < 0.001$) was the only factor associated with clinical success,⁵² together with an adequate source control of the infection (OR, 0.42; 95% CI, 0.14–0.55; $p < 0.001$). In our opinion, ceftolozane–tazobactam represents an attractive option for the treatment of VAP or HAP due to MDR or XDR *P. aeruginosa*. The drug can also be a valuable alternative to carbapenems for the treatment of nosocomial pneumonia due to ESBL-producing *Enterobacteriales*.

Meropenem–Vaborbactam

Meropenem–vaborbactam is a novel non- β -lactam cyclic boronic acid β -lactamase inhibitor combined with a well-known carbapenem, specifically designed to exert high activity against MDR *Enterobacteriales*, including those strains producing Ambler class A, and C β lactamases.⁵³ However, vaborbactam does not expand the activity of meropenem against glucose nonfermenting gram-negative bacilli⁵⁴ and it has no activity against class B and class D carbapenemases.^{55,56}

The in vitro activity of meropenem–vaborbactam has been investigated against more than 10,000 gram-negative isolates from hospitalized patients with pneumonia, including VAP. Among tested agents, meropenem–vaborbactam showed the highest susceptibility rates against *Enterobacteriales* isolates (98.0%). In addition, against *P. aeruginosa* isolates, meropenem–vaborbactam was the most active β -lactam tested (82.1% susceptible), with amikacin (86.0%) and colistin (99.4%) showing higher susceptibility rates.⁵⁷ Similar results were also observed in another U.S. study including gram-negative isolates from respiratory tract.⁵⁸

In a phase 1 study, plasma clearance of meropenem and vaborbactam was similar, suggesting that concomitant administration does not impact plasma pharmacokinetics of either drugs, regardless of the dosage or schedule.^{59,60} Both drugs were excreted by the kidneys, thus requiring proportional dose reduction in patients with renal impairment.⁵⁹ Regarding its use in respiratory tract infection, meropenem–vaborbactam showed a good pulmonary penetration as suggested by the AUC values of 63 and 53%, respectively,

detected in ELF and total plasma concentration of healthy volunteers receiving three doses of meropenem–vaborbactam.⁶¹

The efficacy and safety of meropenem–vaborbactam for HAP and VAP has been evaluated in the Targeting Antibiotic Non-susceptible Gram-Negative Organisms (TANGO)-2 trial, a multicenter, randomized open-label phase 3 study comparing meropenem–vaborbactam versus best available treatment (BAT) for the treatment of confirmed or suspected serious infections due to carbapenem-resistant *Enterobacteriales* (CRE).⁶² Overall, 43 out of 77 eligible patients had confirmed CRE infections and were randomized 2:1 to receive either 7 to 14 days of meropenem 2 g plus vaborbactam 2 g every 8 hours as monotherapy or 7 to 14 days of BAT. As there is no standard of care for CRE infections, a wide variety of mono and combination therapies were administered in the BAT group. Of importance, a greater proportion of patients with previous treatment failure randomly received meropenem–vaborbactam (28.1 vs. 0% in BAT). Primary efficacy endpoints for each infection type were based on FDA guidelines in the microbiological CRE-MITT population and included the proportion of patients who achieved overall success (composite endpoint of clinical cure and microbiologic eradication) at TOC in the complicated urinary tract infection (cUTI)/AP subgroup; all-cause mortality in the combined HAP/VAP and bacteremia subgroups; and the proportion of patients with clinical cure at TOC in the complicated intra-abdominal infection (cIAI) subgroup.

In the microbiological CRE-MITT population, meropenem–vaborbactam was associated with higher rates of clinical cure than BAT at both EOT (65.6% [21/32] vs. 33.3% [5/15]; difference, 32.3%; 95% CI: 3.3–61.3%, $p = 0.03$) and TOC (59.4% [19/32] vs. 26.7% [4/15]; difference, 32.7%; 95% CI: 4.6–60.8%; $p = 0.02$). Microbiologic cure was also higher in patients receiving meropenem–vaborbactam in comparison to those receiving BAT (65.6 vs. 40.0%; difference, 25.6%; $p = 0.09$ at EOT).⁶² Of importance, on subgroup of patients with HAP/VAP or bacteremia, day-28 all-cause mortality was numerically lower in the meropenem–vaborbactam group (22.2 vs. 44.4% $p = 0.25$).⁶²

Evidences regarding clinical experiences with meropenem–vaborbactam for the treatment of HAP/VAP are growing.^{63,64} Recently, Alosaimy et al⁶³ described the clinical characteristics and outcomes of 40 patients treated with meropenem–vaborbactam for a variety of gram-negative infections, primarily including CRE. Seventy percent of them were critically ill. The most frequent diagnosis was pneumonia in 32.5% (13/40 patients). Clinical success was achieved in 70% of patients (28/40), with pneumonia being the most common infection type among patients experiencing clinical success (9/28).

The much-awaited post-approval experience regarding meropenem–vaborbactam has been recently reported.⁶⁵ A multicenter, retrospective, cohort study of 131 patients with CRE infections (49 respiratory infection) compared meropenem–vaborbactam ($n = 26$) to ceftazidime–avibactam ($n = 105$). Despite ceftazidime–avibactam was administered as a combination therapy more often, clinical success was

similar between groups (69.2 vs. 62%, $p = 0.49$). Likewise, 30-day and 90-day mortality and rates of AEs did not differ between groups. However, development of resistance was more common with ceftazidime–avibactam monotherapy (3 vs. 0 patients).⁶⁵

In conclusion, meropenem–vaborbactam represents one of the best therapeutic options currently available for treating patients with HAP or VAP due to CRE pathogens.

Imipenem–Relebactam

Relebactam is a novel bicyclic diazabicyclooctane β -lactamase inhibitor structurally related to avibactam.⁶⁶ It shows potent activity against classes A⁶⁷ and C β -lactamases. However, it does not impede hydrolysis mediated by class B carbapenemases and shows minimal activity against class D oxacillinases (e.g., OXA-48 enzymes).⁶⁸

The addition of relebactam to imipenem potentiates the activity of the carbapenem against gram-negative bacteria, including imipenem nonsusceptible strains, *P. aeruginosa* and some β -lactamase-producing *Enterobacteriales* such as ESBL or KPC producers. However, the combination showed irrelevant activity against *A. baumannii* or *S. maltophilia*.^{69,70} As for in vitro studies, relebactam improves the activity of imipenem against Ambler class A ESBL-producing (2- to 16-fold reduction) or KPC-producing *Enterobacteriales* (32- to 128-fold MIC reduction),⁷¹ with imipenem–relebactam showing activity against 100% of KPC-producing *K. pneumoniae* isolates.^{67,72,73} Regarding *P. aeruginosa*, the rate of sensitivity to imipenem–relebactam was approximately 90%.⁷⁴ Of importance, 80% of imipenem-resistant isolates displayed recovered susceptibility to imipenem when relebactam was added, especially with strain of *P. aeruginosa* with AmpC production or OprD porin loss.^{71,75}

The standard dosage of imipenem–relebactam is 500 to 250 mg every 6 hours, over 30 minutes of infusion. Dose reduction is recommended if CrCl is lower than 90 mL/min.⁷⁶ Both imipenem and relebactam have good lung tissue penetration, with studies reporting similar relative exposure levels in both the pulmonary epithelial lining and the plasma.^{77,78} Safety and efficacy of imipenem–relebactam for the treatment of HAP/VAP has been investigated in two Phase 3 noninferiority trial. RESTORE-IMI 1 was a multicenter, double-blind phase 3 trial comparing the efficacy and tolerability of imipenem–relebactam to imipenem plus colistin combination in different types of infections (including HAP/VAP) caused by imipenem nonsusceptible pathogen. Patients were randomized 2:1 to 5 to 21 days of imipenem–relebactam or colistin plus imipenem. The primary endpoint in efficacy differed according to each infection type, but for patients with HAP/VAP it was 28-day all-cause mortality. Overall, 47 patients were included in the study (31 in imipenem–relebactam vs. 16 in colistin + imipenem). The most common diagnosis was pneumonia, with VAP being diagnosed in 29% of the patients; the qualifying baseline pathogens were *P. aeruginosa* (77%), followed by *Klebsiella* species (16%) and *Enterobacteriales* (6%).⁷⁹ Favorable overall response was observed in 71% imipenem–relebactam and 70% colistin plus imipenem patients (90% CI, –27.5%, 21.4%),

day-28 favorable clinical response in 71 and 40% (90% CI, 1.3, 51.5), and 28-day mortality in 10 and 30% (90% CI, –46.4, 6.7), respectively. In the subgroup of patients with HAP/VAP, 7 of 8 patients achieved an overall clinical response in the imipenem–relebactam group (87.5%) versus 2 out of 3 in the colistin plus imipenem group (66.7%; 95% CI: 50.8–99.9%). Moreover, patients receiving imipenem–relebactam showed a 20% reduction in terms of 28-day mortality in comparison to those treated with colistin plus imipenem (95% CI, 10.3–60.8%).⁷⁹

RESTORE IMI-2 was the other phase 3 randomized clinical trial specifically evaluating the noninferiority of imipenem–relebactam in comparison to piperacillin–tazobactam for the treatment of hospitalized adult patient with HAP/VAP. A 7-day course of linezolid was also allowed if MRSA was isolated in the baseline respiratory sample. The most common isolated pathogens were *K. pneumoniae* (25.6%) and *P. aeruginosa* (18.9%).⁸⁰ Imipenem–relebactam was found noninferior to piperacillin–tazobactam in the MITT population with respect to the primary outcome of 28-day all-cause mortality (adjusted treatment difference: –5.3%; 95% CI: –11.9 to 1.2%).⁸⁰ Notably, in the predefined subgroup of mechanically ventilated patients or those with an APACHE II score greater than 15, day-28 mortality rate was found significantly lower in patients receiving imipenem–relebactam in comparison to piperacillin/tazobactam.⁸⁰

In our opinion, imipenem–relebactam should always be considered for the treatment of suspected or confirmed HAP/VAP caused by gram-negative bacilli with resistance to carbapenem.

Cefiderocol

Cefiderocol is a novel siderophore cephalosporin active against gram-negative bacilli, including *Enterobacteriales* and nonfermenters exhibiting difficult-to-treat resistance phenotype. This wide spectrum of activity is dependent on its unique properties that enable cefiderocol to remain stable in the presence of all classes of β -lactamases including Ambler Class A, B, C, and D β -lactamases. The chemical structure of cefiderocol is similar to that of cefepime and ceftazidime, with the addition of a catechol moiety at the C-3 position of the side chain that forms a chelating complex with ferric iron. This process facilitates high concentration of the antibiotic in the periplasmic space (“Trojan horse” strategy),^{81,82} allowing cefiderocol to efficiently inhibit the synthesis of peptidoglycans.⁸³ The in vitro activity of cefiderocol against several multidrug-resistant pathogens has been investigated in a large surveillance program (SIDERO-WT).^{84–86} Overall, more than 28,000 gram-negative isolates from various sources (including VAP) were randomly collected and tested. More than 99% of the tested strains showed low MIC values against cefiderocol (MIC₉₀ between 0.25 and 1 μ g/mL for *E. coli*, *Klebsiella* spp., *Citrobacter* spp., *Enterobacter* spp., and *Serratia* spp., from 0.03 to 1 μ g/mL against *P. aeruginosa*, *B. cepacia*, and *S. maltophilia*, 1 to 4 μ g/mL against *A. baumannii*).^{86,87}

Cefiderocol has a linear pharmacokinetic curve. It is excreted nonmetabolized into urine for 60 to 70%; dosage

adjustments are required for patients with severe impairment of renal function.⁸⁸ The pulmonary exposition to ceftiderocol in healthy individuals is similar to ceftazidime (ELF/plasma AUC ratio of 0.239 for ceftiderocol vs. 0.229 for ceftazidime).⁸⁹ A dose of 2 g every 8 hours is suggested on the basis of pharmacokinetic/pharmacodynamic modeling and simulation.⁸⁸

The efficacy of ceftiderocol in patients with HAP and VAP caused by gram-negative bacilli was evaluated in the APEKS-NP study, a phase 3 double-blind, randomized, noninferiority trial. The patients were randomized to ceftiderocol 2 g every 8 hours or to meropenem 2 g every 8 hours, both as 3-hour infusion. In this study, linezolid was administered for at least 5 days, while ceftiderocol or meropenem was administered for 7 to 14 days. The primary endpoint was all-cause mortality at 14 days for the microbiological ITT population, with a preestablished noninferiority margin of 12.5%. In this study, 123 out of 292 patients (42%) of the ITT population were diagnosed with VAP with *K. pneumoniae*, *P. aeruginosa*, and *A. baumannii* being the most commonly isolated pathogens.⁹⁰ Ceftiderocol was found noninferior to meropenem with respect to all-cause mortality at day 14 (12.4% in ceftiderocol arm vs. 11.6% in meropenem arm, adjusted treatment difference in ITT population of 0.8%, 95% CI: -6.6 to 8.2; $p = 0.002$). All-cause mortality on day 28 and safety endpoints were similar between the two treatment arms.⁹⁰

Another significant contribution of ceftiderocol to modern antimicrobial chemotherapy has also been treating serious carbapenem-resistant infections, including HAP and VAP.^{91,92} The CREDIBLE-CR study was an open-label, international, multicenter, pathogen-oriented phase 3 trial in which ceftiderocol 2 g every 8 hours was compared with the BAT for treating HAP, VAP, cUTI, or bloodstream infections due to carbapenem-resistant gram-negative bacilli. Patients were randomized 2:1 to receive ceftiderocol or BAT. Nosocomial pneumonia was present in 45% of the patients and about one quarter of them had VAP. The most common isolates were *A. baumannii* (46%, 54 patients), *K. pneumoniae* (33%, 39 patients), and *P. aeruginosa* (19%, 22 patients). In the modified intention-to-treat (mITT) population, clinical cure rates at TOC were comparable between the two arms (50%, 95% CI: 33.8–66.2 in the ceftiderocol arm vs. 53%, 28.9–75.6 in the BAT arm). Similar results were also observed in the carbapenem-resistant microbiological ITT subgroup of patients with HAP and VAP, in which the primary outcome of clinical cure at 7 ± 2 days following the end of treatment was met in 50 and 53% of patients. However, regarding patients with HAP and VAP, the mortality at the end of the study was higher in the ceftiderocol group (42%) versus BAT (18%), mainly when the infecting pathogen was *A. baumannii*.⁹² On the basis of these results, a warning of increased all-cause mortality for patients with carbapenem-resistant *A. baumannii* infections treated with ceftiderocol monotherapy has been released.⁹³ A further RCT (the open-label GAME CHANGER trial) evaluating the efficacy of ceftiderocol in comparison to BAT for the treatment of bloodstream infections caused by MDR gram-negative pathogens is currently ongoing (NCT 03869437).

Case reports of patients with HAP or VAP treated with ceftiderocol in compassionate use have highlighted unique challenges in managing infections due to MDR gram-negative bacilli.^{94–96} Recently, an Italian case series investigated 10 ceftiderocol-treated critically ill patients who suffered serious carbapenem-resistant infections (40% of them had VAP). Thirty-day clinical success and survival rates were 70 and 90%, respectively. Only 2 out of 10 patients had a microbiological failure.⁹⁷ Of note, half of the patients included in this study were ICU admitted because of COVID-19 pneumonia.⁹⁷

In conclusion, we believe that ceftiderocol is a promising cephalosporin with an important potential for the treatment of HAP and VAP, thanks to the very broad spectrum of activity against carbapenem-resistant gram-negative bacteria, including MBL-producing *Enterobacterales* and MDR *P. aeruginosa*.

Other Antibiotics

Tedizolid

Tedizolid phosphate is an oxazolidinone prodrug that is rapidly converted by endogenous phosphatases to the active moiety tedizolid.⁹⁸ Similar to linezolid, tedizolid works by binding to the 23S rRNA of the 50S subunit preventing the formation of the 70S initiation complex and inhibiting protein synthesis.⁹⁹ The oral bioavailability of tedizolid is more than 90%. Tedizolid does not need to be modified in patients with renal impairment, hepatic impairment, or on hemodialysis.^{100,101} Its half-life is approximately 12 hours and steady-state concentrations are achieved within 3 days. Peak plasma tedizolid concentrations are achieved at the end of the 1-hour IV infusion of tedizolid phosphate.^{101,102} The majority of elimination occurs via the liver, with 82% of the dose recovered in feces and 18% in urine. There is no effect on cytochrome P450 (CYP) enzymes and no potential drug interactions with tedizolid were identified by in vitro CYP inhibition or induction studies.^{101,103} Compared with linezolid, tedizolid seems to present a lower incidence of gastrointestinal AEs and bone marrow suppression.¹⁰³ Tedizolid is a reversible inhibitor of monoamine oxidase (MAO) in vitro, but interactions with MAO inhibitors could not be evaluated in phase 2 and 3 trials, as subjects taking such medications were excluded. Drug interaction studies to determine effects of 200 mg oral tedizolid phosphate at steady state on pseudoephedrine and tyramine pressor effects were conducted in healthy volunteers. No meaningful changes in blood pressure or heart rate with pseudoephedrine were observed in the healthy volunteers, and no clinically relevant increase in tyramine sensitivity was observed.^{101,104} Tolerability in clinically important subpopulations (obese, elderly, renal impairment, hepatic disease/impairment) appears to be comparable to the overall population.¹⁰⁵ Tedizolid is approved by the FDA and the European Medicines Agency (EMA) for treating acute bacterial skin and skin structure infections (ABSSSIs) as an oral or IV 200-mg dose administered once daily for 6 days.⁹⁸ Tedizolid exhibits activity against a broad spectrum of gram-positive pathogens, including PRP, vancomycin-resistant *Enterococcus*

spp., MRSA, vancomycin-resistant *S. aureus*; in vitro potency of tedizolid was 4- to 8-fold greater than linezolid across a range of gram-positive pathogens.¹⁰⁶⁻¹¹⁰ The incorporation of a D-ring substituent and a hydroxymethyl group in place of acetamide gives tedizolid activity against some linezolid-resistant pathogens.¹⁰¹ The Surveillance of Tedizolid Activity and Resistance program tested more than 11,000 gram-positive clinical isolates from the United States and Europe, including respiratory tract specimens, and found that tedizolid inhibited 99.7% of isolates at a MIC of ≤ 0.5 mg/L.¹¹¹ An international study across 96 international medical centers showed a high potency of tedizolid against *S. aureus* and *S. pneumoniae* tested for susceptibility by reference broth microdilution.¹¹² Tedizolid demonstrates excellent pulmonary penetration in adult healthy volunteers, with ELF concentrations higher than free plasma concentrations for the entire dosing interval and an approximately 40-fold ELF-to-plasma penetration ratio.¹¹³ Recently, a phase 3, randomized, double-blind study conducted at 122 study sites in 32 countries from 2014 to 2018 compared tedizolid to linezolid for ventilated gram-positive HAP or VAP (vHAP/VAP).¹¹⁴ Patients were randomized 1:1 to tedizolid phosphate 200 mg once daily as a 60-minute IV infusion for 7 days or linezolid 600 mg twice daily as a 60-minute IV infusion for 10 days (patients with concurrent gram-positive bacteremia received 14-day treatment). The primary efficacy end points were day-28 all-cause mortality and investigator-assessed clinical response at the TOC visit (7-14 days after last study drug infusion or time of failure) in the ITT population. Overall, 726 patients were randomized (tedizolid, $n = 366$; linezolid, $n = 360$). Tedizolid was noninferior to linezolid for day-28 all-cause mortality rate: 28.1 and 26.4%, respectively. Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC. In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Both drugs were well tolerated with drug-related AEs occurrence being 8.1 and 11.9% of patients who received tedizolid and linezolid, respectively.¹¹⁴ A recently published study suggests tedizolid as a promising therapeutic option for the treatment of cystic fibrosis-associated MRSA/methicillin-susceptible *S. aureus* infections, having potent in vivo activity and low resistance potential.¹¹⁵

Ceftaroline-Avibactam

Ceftaroline is a fifth-generation cephalosporin providing high activity against common respiratory pathogens, including MRSA, PRP, and non-ESBL-producing *Enterobacterales*. Limited or no activity has been observed against anaerobes, ESBL and AmpC producing strains, *A. baumannii*, and *P. aeruginosa*.¹¹⁶

When combined with avibactam, ceftaroline resists the hydrolysis from class A (including ESBLs, KPC), class C (AmpC), and some class D β -lactamases, while preserving its gram-positive activity.

Although the in vitro activity of ceftaroline-avibactam support furthers the evaluation of this drug as an effective treatment option for HAP and VAP, there are no studies performed so far regarding the use of this new drug for

nosocomial pneumonia. If future studies will show positive results, this drug could represent an attractive single-agent option for the treatment of VAP or HAP due to mixed gram-positive and gram-negative pathogens.

Plazomicin

Plazomicin is a new semisynthetic aminoglycoside resistant to inactivation by aminoglycoside-modifying enzymes. Therefore, it is active against a larger proportion of CRE than those with amikacin, tobramycin, or gentamycin.¹¹⁷ However, similar to other aminoglycosides, it is affected by 16s ribosomal ribonucleic acid (rRNA) methyltransferase.¹¹⁸

In vitro, plazomicin was active against more than 95% of *Enterobacterales* strains (MIC_{50/90}, 0.5/1 mg/L) with susceptibility breakpoint lower than 2 mg/L.¹¹⁹ Regarding *P. aeruginosa* and *Acinetobacter* spp., plazomicin exhibited MIC_{50/90} comparable to amikacin. Likewise, MIC_{50/90} against gram-positive bacteria, including MRSA, was similar to gentamicin (≤ 2 mg/L). However, no activity has been found against anaerobes, *Enterococcus*, *Streptococcus*, and *Stenotrophomonas*.¹²⁰

Plazomicin is currently FDA approved at a dosage of 15 mg/kg IV for the treatment of cUTI including AP caused by aerobic gram negative. The pharmacokinetics is similar to that of other aminoglycosides with low plasma protein binding (20%)¹²¹ and low lung penetration (13%).¹²²

Clinically, the CARE trial evaluated the efficacy and safety of plazomicin compared with colistin for the treatment of BSI, HAP/VAP, and cUTI caused by CRE. The most common microbiologic isolate was carbapenem-resistant *K. pneumoniae* in both arms. Among patients with HAP/VAP, the primary end point (a composite endpoint of death from any cause at 28 days or clinically significant disease-related complications in the microbiologic mMITT) occurred in 67% in the plazomicin arm (two out of three patients) and in 40% (two out of five patients) in the colistin arm (difference, 27%; 95% CI, -48 to 82). Additionally, Serious Adverse Events (SAEs) were significantly lower in the plazomicin group than in the colistin one (50% plazomicin vs. 81% colistin).¹²³

Although plazomicin has emerged as a valuable option in the treatment of HAP/VAP caused by CRE, the FDA denied the approval for this indication, mainly due to the small sample size of the HAP subgroup in the CARE trial (five VAPs in the colistin group and three in the plazomicin group).¹²⁴ In our opinion, because plazomicin shows a wide spectrum of activity including MRSA and MDR gram negatives, it could offer an important new treatment option as part of a combination regimen for patients with HAP and VAP.¹²⁵

Aztreonam-Avibactam

Aztreonam is the only β -lactam-providing activity against metallo- β -lactamases (MBL), but it is hydrolyzed by most ESBLs or AmpC enzymes, which are often coproduced in carbapenem-resistant strains.¹²⁶ The association with avibactam confers aztreonam stability with respect to most of MDR pathogens, including those co-harboring class A, C, and D β -lactamases.^{127,128} Antimicrobial activity of aztreonam-avibactam against gram-negative bacteria collected from patients hospitalized with pneumonia has been recently

investigated.¹²⁹ Overall, 99.9% of the *Enterobacterales* were inhibited by aztreonam–avibactam, even when isolates were NDM, KPC, or OXA-48 producers.^{129–131} As for *P. aeruginosa*, more than 75% of tested isolates were in vitro susceptible to aztreonam–avibactam, showing an MIC value lower than 8 mg/L.¹²⁹

To the best of our knowledge, there are no studies evaluating lung distribution of aztreonam–avibactam in healthy subject. However, a good lung penetration of aztreonam–avibactam could be presumed, as pharmacokinetics parameters are similar when aztreonam is given alone or in combination with avibactam.^{132,133}

The drug has not been FDA or EMA approved, as the pivotal trials evaluating aztreonam–avibactam for the treatment of serious gram-negative infections are currently ongoing.¹³⁴ However, waiting for more robust data, aztreonam has been used in combination with ceftazidime–avibactam for the treatment of serious infections caused by MBL-producing strains.^{135–137}

In a prospective multicenter study performed in Italy and Greece, and including 82 patients with bloodstream infections due to NDM-producing *Enterobacterales* (source of the infection was the respiratory tract in 10% of the cases), ceftazidime–avibactam plus aztreonam was associated with lower 30-day mortality rate, lower clinical failure at 14 days, and shorter length of hospital stay when compared with regimens using other active agents. In another retrospective study including 10 patients with serious CRE infections (2 out of 10 were HAP) treated with ceftazidime–avibactam plus aztreonam, clinical success was achieved in 60% (6/10) of the cases. When only patients with HAP were analyzed, one experienced clinical success and the other died, although death was not considered as infection related.¹³⁸

Cefoperazone–Sulbactam

Cefoperazone–sulbactam is a combination of a third-generation cephamycin and an old β -lactamase inhibitors. It is active against *Enterobacterales* and *Pseudomonas* spp. Sulbactam confers to the combination activity against *Acinetobacter* and anaerobes and provides to cefoperazone more stability to some β -lactamases and mitigates the high inoculum effect.¹³⁹ In a RCT from Taiwan enrolling 166 patients, cefoperazone–sulbactam was administered at the dosage of 2 g every 12 hours versus cefepime for the treatment of HAP and healthcare-associated pneumonia. No difference was found between the two groups in the ITT and safety analysis. The correct evaluation of the microbiological analysis was limited by the small number ($n = 16$) of bacterial isolates.¹⁴⁰ The same group from Taiwan enrolled 410 patients in a retrospective study comparing the use of cefoperazone–sulbactam versus piperacillin/tazobactam for the treatment of HAP and VAP. The primary outcome was clinical cure defined as the proportion of patients not needing adjunctive antibiotic therapy and with improved or resolved symptoms or signs 7 days after the end of treatment. Cefoperazone–sulbactam was found to be as clinically effective as piperacillin/tazobactam, although in cefoperazone–

sulbactam group the Charlson Comorbidity Index and APACHE II scores were higher (Charlson's score: 6.5 ± 2.9 vs. 5.7 ± 2.7 , $p < 0.001$; APACHE II score: 21.4 ± 6.2 vs. 19.3 ± 6.0 , $p = 0.002$).¹⁴¹

Eravacycline

Eravacycline is a novel fluorocycline, structurally similar to tigecycline. It is available in oral and IV formulation. Its spectrum of activity ranges from gram-positive to gram-negative and anaerobic bacteria with the exception of *P. aeruginosa*.¹⁴² Notably, eravacycline exerts its activity against *A. baumannii* isolates resistant to sulbactam.¹⁴³ A low rate of *C. difficile* infection is reported during the therapy with eravacycline.¹⁴⁴ For intra-abdominal infections, robust data come from the IGNITE 1 and IGNITE4 phase 3 clinical trials where eravacycline was found noninferior to ertapenem and meropenem.¹⁴⁵ ELF concentrations of eravacycline were found to be greater than plasma levels by six- and fifty-fold in healthy adult volunteers receiving the IV formulation in a phase 1 study.¹⁴⁶ Further investigations are needed to support the use of eravacycline in respiratory infections.

Murepavadin

Formerly known as POL7080, murepavadin is the first molecule of a novel class of pathogen-specific antibiotic with a nonlytic mechanism of action called “outer membrane protein targeting antibiotics.” Murepavadin inhibits the formation of the lipopolysaccharide causing cell death.¹⁴⁷ Several studies have assessed the high activity against *P. aeruginosa* in vitro,¹⁴⁸ also in MDR strains.¹⁴⁹ In vitro activity of murepavadin against colistin-resistant *P. aeruginosa* showed MIC₅₀ and MIC₉₀ 0.125 and 0.5 mg/L, respectively. MIC distributions for colistin-resistant and colistin-susceptible were similar, indicating no cross-resistance.¹⁵⁰ Murepavadin was well tolerated at doses up to 4.5 mg/kg of body weight in a phase 1 study. The most common AE was paresthesia. In animal models, murepavadin showed good penetration into ELF (ELF/plasma ratio of 24.4% for total drug and 108.9% for free drug) with ELF concentration similar to free plasma concentration.¹⁵¹ In a phase 2 trial, murepavadin was coadministered to the standard of care treatment for VAP caused by *P. aeruginosa* and high rate of clinical cure and low rate of mortality at day 28 was observed.¹⁵² Dose adjustment is warranted in impaired renal function, but safety was confirmed in patients with different degree of renal function.¹⁴⁷ Results from two phase 3 trials (NCT03409679 and NCT03582007) for the treatment of HAP and VAP are expected.

Iclaprim

Iclaprim is a dihydrofolate reductase (DR) inhibitor antibiotic with a 20-fold greater ability to inhibit DR compared with trimethoprim and as such not needing the combination with a sulfonamide. Iclaprim exhibits in vitro bactericidal activity against gram-positive bacteria including MRSA and some gram-negative (*H. influenzae* and *M. catarrhalis*). A phase 1 study showed a rapid diffusion of iclaprim into the pulmonary compartments and an ELF drug concentration 20- to 40-

fold greater than in serum.^{153,154} Iclaprim was studied in five clinical studies for treating serious skin infections (one phase 2 and four phase 3 trials) where it showed noninferiority versus vancomycin. Efficacy and safety of iclaprim in the treatment of HAP and VAP were investigated in a phase 2 study in which iclaprim was found noninferior to vancomycin in terms of clinical cure rates and safety profile.¹⁵⁵ A phase 3 clinical trial is needed to further support its safety and efficacy in this indication.

New Investigational Agents

Aerosol administration of antibiotics in HAP and VAP offers the advantage of achieving high concentration in the site of the infection, especially in infections caused by pathogens susceptible only to antibiotics with a weak lung penetration, and to mitigate AEs of systemic toxicity.¹⁵⁶ Inhaled molecules may be delivered through liposomes allowing a slow release of the molecule with a constant high concentration.¹⁵⁷ Aerosol therapy may be performed with new molecules or with optimized inhalation formulation of known antibiotics. While some antibiotics have long time been used in this formulation, new ones are under study evaluation due to the increasing incidence of bacterial resistance and the utility of combination regimens for MDR pathogens. A promising molecule is liposomal ciprofloxacin, available in the rapid-release formulation (Lipoquin, ARD-3100) and in the slow-release formulations (Pulmaquin, ARD-3150). In the ORBIT-2 trial, the rapid-release formulation showed a good safety and tolerability profile in 22 cystic fibrosis patients.¹⁵⁸ The ORBIT-3 and ORBIT-4 international phase 3 randomized, double-blind, placebo-controlled trials assessed the safety and efficacy of the slow-release formulation for the treatment of *P. aeruginosa* in non-cystic fibrosis bronchiectasis patients. While in the ORBIT-4 there was a significant longer time to exacerbation, ORBIT-3 did not yield the same result.¹⁵⁹ Further researches are needed to establish the place in therapy of liposomal ciprofloxacin. A phase 2 double-blind placebo-controlled trial assessed the safety and efficacy of the amikacin-fosfomycin inhalation system (AFIS) as adjunctive therapy to IV therapy in the treatment of VAP caused by gram-negative bacteria including *A. baumannii*, *P. aeruginosa*, *S. maltophilia*, and *Enterobacterales*. AFIS significantly reduced bacterial burden (tracheal culture at day 3 positive in 19% of patients in the AFIS group vs. 40% in the placebo group, $p < 0.001$), but clinical outcome between the two groups was not superior in the AFIS group.¹⁶⁰ Arbekacin is a broad-spectrum aminoglycoside with activity against MRSA and *P. aeruginosa*. In an animal comparative study versus amikacin for the treatment of *P. aeruginosa* VAP, nebulized arbekacin (ME1100) showed superiority in the survival rate compared with placebo and amikacin groups.¹⁶¹ Some positive experiences from Japan report the use of arbekacin, used in the nebulized formulation for the treatment of MRSA and MDR gram-negative pulmonary infections.¹⁶² The fixed-dose combination of aztreonam and tobramycin has shown good stability and synergistic antibacterial effect in in vitro simulation against MDR *P. aeruginosa* and *A. baumannii*.¹⁶³ A new frontier in the management of difficult-to-treat infections and

pathogens is the use of bacteriophages. The use of phage-cocktail or the phage-antibiotic combination have been proposed to overcome the growing issue of phage and antibiotic resistance.¹⁶⁴ In an in vitro study comparing inhaled combination of phage PEV20 with different antibiotics against *P. aeruginosa*, ciprofloxacin and, to a less extent, amikacin exhibited synergistic action.¹⁶⁵ Bacterial load in mechanically ventilated porcine model and mouse lungs infected by *P. aeruginosa* was reduced from 1.5-log ($p < 0.001$) to 5.9 log-10 ($p < 0.005$) after the inhalation of phage cocktail and phage-ciprofloxacin combination, respectively.^{166,167} Phages have also been successfully used in animal models in the prophylaxis of MRSA pneumonia. Derivatives of phages such as endolysins have been used in mouse models in *Streptococcus pneumoniae* infections with different results depending on the nebulizer.¹⁶⁸

Conclusion

Management of patients with HAP and VAP requires prompt and adequate antibiotic administration and exposure. During the last decade, the progressive increase of nosocomial respiratory tract infections caused by MDR organisms has been associated with delays in the prescription of an adequate antibiotic treatment and increased mortality, representing a major concern. New approved and investigational agents for the treatment of respiratory tract infections represent promising options to preserve and enhance our antibiotic armamentarium. The most attractive characteristic of new drugs is the broad-spectrum activity against MDR organisms, particularly gram negatives, which still represent a major challenge in clinical practice. The efficacy of these agents in real life should be further investigated. In particular, studies regarding the potential opportunity for a monotherapy in patients with infections by MDR gram-negative pathogens are needed. Positioning and differentiation of new treatment options, along with the optimization of available therapeutic options, are needed to incorporate these drugs in daily clinical use to face the challenge of antimicrobial resistance in patients with HAP and VAP.

In conclusion, several newly approved agents hold promise for the treatment of HAP and VAP and hopefully new agents will enrich our antimicrobial arsenal in the next years. Targeted pharmacokinetic and clinical studies in real-life scenario of HAP and VAP are important to position these new agents in clinical practice, whereas vigilant use will ensure their longevity in our armamentarium.

Conflict of Interest

Outside the submitted work, D.N.G. reports investigator-initiated grants by Pfizer Inc. and Gilead Italia. Outside the submitted work, M.B. has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Shionogi, Tetrphase, Nabriva. The other authors did not report conflicts of interest relevant to this paper.

References

- 1 Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). *Eur Respir J* 2017;50(03):1700582
- 2 American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171(04):388–416
- 3 Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016;63(05):e61–e111
- 4 Masterton RG, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2008;62(01):5–34
- 5 Bakhru RN, Wiebe DJ, McWilliams DJ, Spuhler VJ, Schweickert WD. An environmental scan for early mobilization practices in U.S. ICUs. *Crit Care Med* 2015;43(11):2360–2369
- 6 Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. *Eur J Clin Microbiol Infect Dis* 2017;36(11):1999–2006
- 7 Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect Dis* 2013;13(08):665–671
- 8 Wilke M, Grube RF, Bodmann KF. Guideline-adherent initial intravenous antibiotic therapy for hospital-acquired/ventilator-associated pneumonia is clinically superior, saves lives and is cheaper than non guideline adherent therapy. *Eur J Med Res* 2011;16(07):315–323
- 9 Tseng CC, Liu SF, Wang CC, et al. Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-associated pneumonia. *Am J Infect Control* 2012;40(07):648–652
- 10 Venditti M, Falcone M, Corrao S, Licata G, Serra P Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. *Ann Intern Med* 2009;150(01):19–26
- 11 Rolain JM, Abat C, Jimeno MT, Fournier PE, Raoult D. Do we need new antibiotics? *Clin Microbiol Infect* 2016;22(05):408–415
- 12 Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. *JAMA* 2009;302(21):2323–2329
- 13 Chung DR, Song JH, Kim SH, et al; Asian Network for Surveillance of Resistant Pathogens Study Group. High prevalence of multi-drug-resistant nonfermenters in hospital-acquired pneumonia in Asia. *Am J Respir Crit Care Med* 2011;184(12):1409–1417
- 14 Delle Rose D, Pezzotti P, Fortunato E, et al. Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals. *Eur J Clin Microbiol Infect Dis* 2016;35(09):1531–1539
- 15 Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomes. *BMC Infect Dis* 2012;12:268
- 16 Riyat MS. Hodgkin's disease in Kenya. *Cancer* 1992;69(04):1047–1051
- 17 Giacobbe DR, De Rosa FG, Del Bono V, et al. Ceftobiprole: drug evaluation and place in therapy. *Expert Rev Anti Infect Ther* 2019;17(09):689–698
- 18 Zbinden R, Pünter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. *Antimicrob Agents Chemother* 2002;46(03):871–874
- 19 Lovering AL, Gretes MC, Safadi SS, et al. Structural insights into the anti-methicillin-resistant *Staphylococcus aureus* (MRSA) activity of ceftobiprole. *J Biol Chem* 2012;287(38):32096–32102
- 20 Falcó V, Burgos J, Almirante B. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. *Expert Opin Pharmacother* 2018;19(13):1503–1509
- 21 Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. *Antimicrob Agents Chemother* 2007;51(09):3089–3095
- 22 Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2007;51(07):2621–2624
- 23 Cillóniz C, Dominedò C, Garcia-Vidal C, Torres A. Ceftobiprole for the treatment of pneumonia. *Rev Esp Quimioter* 2019;32(Suppl 3):17–23
- 24 Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. *Clin Pharmacokinet* 2016;55(12):1507–1520
- 25 Lupia T, Pallotto C, Corcione S, Boglione L, De Rosa FG. Ceftobiprole perspective: current and potential future indications. *Antibiotics (Basel)* 2021;10(02):170
- 26 Medicines and Healthcare Products Regulatory Agency. Basilea Medical Ltd. Public assessment report, Zevtera 500 mg powder for concentrate for solution for infusion. Accessed October 30, 2021 at: <https://globenewswire.com/news-release/2018/03/06/1415442/0/en/Basilea-reports-launch-of-antibiotic-Zevtera-ceftobiprole-in-Argentina-by-Grupo-Biotoscana.html>
- 27 Bäckström T, Panagiotidis G, Beck O, et al. Effect of ceftobiprole on the normal human intestinal microflora. *Int J Antimicrob Agents* 2010;36(06):537–541
- 28 Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. *Clin Infect Dis* 2014;59(01):51–61
- 29 Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. *Int J Antimicrob Agents* 2012;39(03):240–246
- 30 van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β -lactam/ β -lactamase inhibitor combinations. *Clin Infect Dis* 2016;63(02):234–241
- 31 Cabot G, Bruchmann S, Mulet X, et al. *Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. *Antimicrob Agents Chemother* 2014;58(06):3091–3099
- 32 Giacobbe DR, Bassetti M, De Rosa FG, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva) Ceftolozane/tazobactam: place in therapy. *Expert Rev Anti Infect Ther* 2018;16(04):307–320
- 33 Rodríguez-Pardo D, Escolà-Vergé L, Sellarès-Nadal J, Corona PS, Almirante B, Pigrau C. Periprosthetic joint infection prophylaxis in the elderly after hip hemiarthroplasty in proximal femur fractures: insights and challenges. *Antibiotics (Basel)* 2021;10(04):429

- 34 Livermore DM, Mushtaq S, Meunier D, et al; BSAC Resistance Surveillance Standing Committee. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, *Pseudomonas aeruginosa* and non-fermenters from the British Isles. *J Antimicrob Chemother* 2017;72(08):2278–2289
- 35 Goodlet KJ, Nicolau DP, Nailor MD. *In vitro* comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2017;61(12):e01350-17
- 36 Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. *In vitro* and *in vivo* activities of a new cephalosporin, FR264205, against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2007;51(03):826–830
- 37 Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and *Pseudomonas aeruginosa* with various resistance patterns isolated in U.S. hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. *Microb Drug Resist* 2018;24(05):563–577
- 38 Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF. Activity of ceftolozane-tazobactam and comparators against *Pseudomonas aeruginosa* from patients in different risk strata - SMART United States 2016–2017. *J Glob Antimicrob Resist* 2020;20:209–213
- 39 Sutherland CA, Nicolau DP. Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy. *J Thorac Dis* 2017;9(01):214–221
- 40 Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers. *Diagn Microbiol Infect Dis* 2019;94(01):93–102
- 41 Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D. Activity of ceftolozane-tazobactam against *Pseudomonas aeruginosa* and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. *Antimicrob Agents Chemother* 2018;62(03):e02125-17
- 42 Castanheira M, Doyle TB, Mendes RE, Sader HS. Comparative activities of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum β -lactamases from U.S. hospitals. *Antimicrob Agents Chemother* 2019;63(07):e00160-19
- 43 Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). *J Antimicrob Chemother* 2017;72(05):1386–1395
- 44 Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). *Int J Antimicrob Agents* 2014;43(06):533–539
- 45 Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. *J Antimicrob Chemother* 2012;67(10):2463–2469
- 46 Petraitis V, Petraitiene R, Naing E, et al. Ceftolozane-tazobactam in the treatment of experimental *Pseudomonas aeruginosa* pneumonia in persistently neutropenic rabbits: impact on strains with genetically defined mechanisms of resistance. *Antimicrob Agents Chemother* 2019;63(09):e00344-19
- 47 Zerbaxa EMA. Summary of product characteristics. Accessed October 30, 2021 at: https://www.ema.europa.eu/en/documents/product-information/zerbaxa-epar-product-information_en.pdf
- 48 Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* 2019;19(12):1299–1311
- 49 Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Systematic literature review of real-world evidence of ceftolozane/tazobactam for the treatment of respiratory infections. *Infect Dis Ther* 2021;10(03):1227–1252
- 50 Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis* 2020;71(02):304–310
- 51 Bassetti M, Castaldo N, Cattelan A, et al; CEFTABUSE Study Group. Ceftolozane/tazobactam for the treatment of serious *Pseudomonas aeruginosa* infections: a multicentre nationwide clinical experience. *Int J Antimicrob Agents* 2019;53(04):408–415
- 52 Bassetti M, Vena A, Giacobbe DR, et al; CEFTABUSE Study Group. Ceftolozane/Tazobactam for treatment of severe ESBL-producing Enterobacteriales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study). *Open Forum Infect Dis* 2020;7(05):a139
- 53 Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M. Meropenem/vaborbactam: a next generation β -lactam β -lactamase inhibitor combination. *Expert Rev Anti Infect Ther* 2020;18(07):643–655
- 54 Bassetti M, Vena A, Sepulcri C, Giacobbe DR, Peghin M. Treatment of bloodstream infections due to gram-negative bacteria with difficult-to-treat resistance. *Antibiotics (Basel)* 2020;9(09):E632
- 55 Hecker SJ, Reddy KR, Trovov M, et al. Discovery of a cyclic boronic acid β -lactamase inhibitor (RPX7009) with utility vs class a serine carbapenemases. *J Med Chem* 2015;58(09):3682–3692
- 56 Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. *Antimicrob Agents Chemother* 2017;61(11):e01443-17
- 57 Shortridge D, Deshpande LM, Duncan LR, Streit JM, Castanheira M. 1590. Activity of meropenem-vaborbactam and single-agent comparators against Enterobacteriales isolates including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–2019). *Open Forum Infect Dis* 2020;7(Suppl 1):S792–S792
- 58 Carvalhaes CG, Shortridge D, Sader HS, Castanheira M. Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in patients in U.S. hospitals during 2014 to 2018. *Antimicrob Agents Chemother* 2020;64(03):e02177-19
- 59 Rubino CM, Bhavnani SM, Loutit JS, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. *Antimicrob Agents Chemother* 2018;62(04):e02228-17
- 60 Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN. Phase 1 study of the safety, tolerability, and pharmacokinetics of the β -lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. *Antimicrob Agents Chemother* 2016;60(10):6326–6332
- 61 Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. *Antimicrob Agents Chemother* 2015;59(12):7232–7239
- 62 Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. *Infect Dis Ther* 2018;7(04):439–455
- 63 Alosaimy S, Jorgensen SCJ, Lagnf AM, et al. Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. *Open Forum Infect Dis* 2020;7(03):a051

- 64 Shields RK, McCreary EK, Marini RV, et al. Real-world experience with meropenem-vaborbactam (M/V) for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. *Open Forum Infect Dis* 2021;6(Suppl 2):S768–S768
- 65 Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. *Antimicrob Agents Chemother* 2020;64(05):e02313–19
- 66 Olsen I. New promising β -lactamase inhibitors for clinical use. *Eur J Clin Microbiol Infect Dis* 2015;34(07):1303–1308
- 67 Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. *Antimicrob Agents Chemother* 2017;61(09):e00642–17
- 68 Barnes MD, Bethel CR, Alsop J, et al. Inactivation of the *Pseudomonas*-derived cephalosporinase-3 (PDC-3) by relebactam. *Antimicrob Agents Chemother* 2018;62(05):e02406–17
- 69 Lob SH, Hackel MA, Kazmierczak KM, et al. *In vitro* activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART Global Surveillance Program). *Antimicrob Agents Chemother* 2017;61(06):e02209–16
- 70 Goldstein EJC, Citron DM, Tyrrell KL, Leoncio E, Merriam CV. Comparative *In vitro* activities of relebactam, imipenem, the combination of the two, and six comparator antimicrobial agents against 432 strains of anaerobic organisms, including imipenem-resistant strains. *Antimicrob Agents Chemother* 2018;62(02):e01992–17
- 71 Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem- β -lactamase inhibitor combinations. *Drugs* 2018;78(01):65–98
- 72 Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam is a potent inhibitor of the KPC-2 β -lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. *Antimicrob Agents Chemother* 2018;62(06):e00174–18
- 73 Canver MC, Satlin MJ, Westblade LF, et al. Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae. *Antimicrob Agents Chemother* 2019;63(09):e00672–19
- 74 Sellarès-Nadal J, Eremiev S, Burgos J, Almirante B. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. *Expert Opin Pharmacother* 2021;22(12):1521–1531
- 75 Asempta TE, Nicolau DP, Kuti JL. *In vitro* activity of imipenem-relebactam alone or in combination with amikacin or colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2019;63(09):e00997–19
- 76 EMA. Merck Sharp & Dohme. Recarbrio: EU summary of product characteristics. Accessed October 27, 2021 at: <http://www.ema.europa.eu>
- 77 Rizk ML, Rhee EG, Jumes PA, et al. Intrapulmonary pharmacokinetics of relebactam, a novel β -lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. *Antimicrob Agents Chemother* 2018;62(03):e01411–17
- 78 Karaiskos I, Galani I, Souli M, Giamarellou H. Novel β -lactam- β -lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant gram-negative pathogens. *Expert Opin Drug Metab Toxicol* 2019;15(02):133–149
- 79 Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. *Clin Infect Dis* 2020;70(09):1799–1808
- 80 Titov I, Wunderink RG, Roquilly A, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). *Clin Infect Dis* 2021;73(11):e4539–e4548
- 81 Aoki T, Yoshizawa H, Yamawaki K, et al. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against *Pseudomonas aeruginosa* and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. *Eur J Med Chem* 2018;155:847–868
- 82 Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2016;60(12):7396–7401
- 83 Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. *Clin Infect Dis* 2019;69(Suppl 7):S538–S543
- 84 Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. *In vitro* activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). *Antimicrob Agents Chemother* 2017;61(09):e00093–17
- 85 Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. *In vitro* activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. *Int J Antimicrob Agents* 2019;53(04):456–466
- 86 Yamano Y. *In vitro* activity of cefiderocol against a broad range of clinically important gram-negative bacteria. *Clin Infect Dis* 2019;69(Suppl 7):S544–S551
- 87 Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β -lactamases and carbapenemases. *Antimicrob Agents Chemother* 2018;63(01):e01801–18
- 88 Giacobbe DR, Ciacco E, Girmenia C, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Antimicrobial Therapy) Evaluating cefiderocol in the treatment of multidrug-resistant gram-negative bacilli: a review of the emerging data. *Infect Drug Resist* 2020;13:4697–4711
- 89 Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. *J Antimicrob Chemother* 2019;74(07):1971–1974
- 90 Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* 2021;21(02):213–225
- 91 Fetroja EMA. Cefiderocol prescribing information. 2020. Accessed October 30, 2021 at: https://www.ema.europa.eu/en/documents/product-information/fetroja-epar-product-information_it.pdf
- 92 Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis* 2021;21(02):226–240
- 93 Shionogi. Fetroja (cefiderocol). Prescribing information 2019
- 94 Trearichi EM, Quirino A, Scaglione V, et al; IMAGES Group. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR *Acinetobacter baumannii* and KPC-producing *Klebsiella pneumoniae*: a case report. *J Antimicrob Chemother* 2019;74(11):3399–3401
- 95 Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives. *Antibiotics (Basel)* 2021;10(06):652

- 96 Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriai R, Rybak MJ. Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant gram-negative pathogens. *Pharmacotherapy* 2020;40(12):1228–1247
- 97 Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for *Acinetobacter baumannii* and other carbapenem-resistant gram-negative infections in intensive care unit patients. *Clin Infect Dis* 2021;72(11):2021–2024
- 98 SIVEXTRO tedizolid phosphate: Prescribing information. 2019; Whitehouse Station, NJ: Merck Sharp & Dohme Corp: Accessed October 30, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205436s0051bl.pdf
- 99 Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant *Staphylococcus aureus* strains possessing the CFR methyltransferase gene or ribosomal mutations. *Antimicrob Agents Chemother* 2010;54(12):5337–5343
- 100 Rodríguez-Gascón A, Aguirre-Quiñonero A, Aspiazu MAS, Canut-Blasco A. Pharmacokinetic/Pharmacodynamic analysis of tedizolid phosphate compared to linezolid for the treatment of infections caused by gram-positive bacteria. *Antibiotics (Basel)* 2021;10(07):755
- 101 Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. *Clin Infect Dis* 2015;61(08):1315–1321
- 102 Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. *Pharmacotherapy* 2014;34(03):240–250
- 103 Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. *Antimicrob Agents Chemother* 2011;55(02):583–592
- 104 Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. *Antibiotics (Basel)* 2019;8(03):E137
- 105 Hardalo C, Lodise TP, Bidell M, et al. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections. *Expert Opin Drug Saf* 2018;17(04):359–367
- 106 Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. *Antimicrob Agents Chemother* 2009;53(08):3236–3239
- 107 Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. *Antimicrob Agents Chemother* 2012;56(09):4608–4613
- 108 Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against *Staphylococcus aureus* and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. *J Antimicrob Chemother* 2016;71(01):152–155
- 109 Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK, Mendes RE. Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015). *J Chemother* 2019;31(04):188–194
- 110 Carvalhoes CG, Sader HS, Flamm RK, Streit JM, Mendes RE. Assessment of tedizolid *in vitro* activity and resistance mechanisms against a collection of *Enterococcus* spp. Causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. *Antimicrob Agents Chemother* 2020;64(04):e00175–20
- 111 Bensaci M, Sahn D. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe. *Diagn Microbiol Infect Dis* 2017;87(02):133–138
- 112 Carvalhoes CG, Sader HS, Rhomberg PR, Mendes RE. Tedizolid activity against a multicentre worldwide collection of *Staphylococcus aureus* and *Streptococcus pneumoniae* recovered from patients with pneumonia (2017–2019). *Int J Infect Dis* 2021;107:92–100
- 113 Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. *Antimicrob Agents Chemother* 2012;56(05):2627–2634
- 114 Wunderink RG, Roquilly A, Croce M, et al. A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia. *Clin Infect Dis* 2021;73(03):e710–e718
- 115 Roch M, Varela MC, Taglialegna A, Rosato AE. Tedizolid is a promising antimicrobial option for the treatment of *Staphylococcus aureus* infections in cystic fibrosis patients. *J Antimicrob Chemother* 2020;75(01):126–134
- 116 Russo A. Spotlight on new antibiotics for the treatment of pneumonia. *Clin Med Insights Circ Respir Pulm Med* 2020;14:1179548420982786
- 117 López-Díaz MD, Culebras E, Rodríguez-Avial I, et al. Plazomicin activity against 346 extended-spectrum- β -lactamase/AmpC-producing *Escherichia coli* urinary isolates in relation to aminoglycoside-modifying enzymes. *Antimicrob Agents Chemother* 2017;61(02):e02454–16
- 118 Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. *J Antimicrob Chemother* 2011;66(01):48–53
- 119 Castanheira M, Sader HS, Mendes RE, Jones RN. Activity of plazomicin tested against *Enterobacteriales* isolates collected from U.S. hospitals in 2016–2017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides. *Antimicrob Agents Chemother* 2020;64(05):e02418–19
- 120 Clark JA, Burgess DS. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. *Ther Adv Infect Dis* 2020;7:2049936120952604
- 121 Trang M, Seroogy JD, Van Wart SA, et al. Population pharmacokinetic analyses for plazomicin using pooled data from phase 1, 2, and 3 clinical studies. *Antimicrob Agents Chemother* 2019;63(04):e02329–18
- 122 Cass R, Kostrub CF, Gotfried M, Rodvold K, Tack KJ, Bruss J—A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, plasma pharmacokinetics and lung penetration of intravenous plazomicin in healthy subjects. *Abstr Eur Congr Clin Microbiol Infect Dis* 2013; poster 1637
- 123 McKinnell JA, Dwyer JP, Talbot GH, et al; CARE Study Group. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. *N Engl J Med* 2019;380(08):791–793
- 124 US FDA Advisory Committee. FDA briefing document: plazomicin sulfate injection (NDA 210303). Accessed August 10, 2018 at: <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606039.pdf>
- 125 FDA. ZEMDRI Prescribing Information. 2018 Accessed October 30, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s0001bl.pdf
- 126 Brogden RN, Heel RC. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs* 1986;31(02):96–130

- 127 Shields RK, Doi Y. Aztreonam combination therapy: an answer to metallo- β -lactamase-producing gram-negative bacteria? *Clin Infect Dis* 2020;71(04):1099–1101
- 128 Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. *Antimicrob Agents Chemother* 2017;62(01):e01856–17
- 129 Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M. Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary *Stenotrophomonas maltophilia* isolates from medical centers worldwide. *Antimicrob Agents Chemother* 2020;64(11):e01433–20
- 130 Dupont H, Gaillot O, Goetgheluck AS, et al. Molecular characterization of carbapenem-nonsusceptible enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime-avibactam and aztreonam-avibactam combinations. *Antimicrob Agents Chemother* 2015;60(01):215–221
- 131 Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahn DF, Bradford PA. *In vitro* activity of aztreonam-avibactam against Enterobacteriaceae and *Pseudomonas aeruginosa* isolated by clinical laboratories in 40 countries from 2012 to 2015. *Antimicrob Agents Chemother* 2017;61(09):e00472–17
- 132 Cornely OA, Cisneros JM, Torre-Cisneros J, et al; COMBACTE-CARE Consortium/REJUVENATE Study Group. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. *J Antimicrob Chemother* 2020;75(03):618–627
- 133 Sy SK, Beaudoin ME, Zhuang L, et al. *In vitro* pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. *J Antimicrob Chemother* 2016;71(07):1866–1880
- 134 ClinicalTrials.gov. A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) \pm Metronidazole (MTZ) Versus Meropenem (MER) \pm Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT). 2017
- 135 Tamma PD, Hsu AJ. Defining the role of novel β -lactam agents that target carbapenem-resistant gram-negative organisms. *J Pediatric Infect Dis Soc* 2019;8(03):251–260
- 136 Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β -lactam resistance conferred by metallo- β -lactamases in Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2017;61(09):e01008–17
- 137 Shah PJ, Tran T, Emelogu F, Tariq F. Aztreonam, ceftazidime/avibactam, and colistin combination for the management of carbapenemase-producing *Klebsiella Pneumoniae* bacteremia: a case report. *J Pharm Pract* 2021;34(04):653–657
- 138 Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing *Klebsiella pneumoniae* infection. *J Antimicrob Chemother* 2018;73(04):1104–1106
- 139 Chang PC, Chen CC, Lu YC, et al. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms. *J Microbiol Immunol Infect* 2018;51(02):207–213
- 140 Liu JW, Chen YH, Lee WS, et al. Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia. *Antimicrob Agents Chemother* 2019;63(08):e00023–19
- 141 Chen CH, Tu CY, Chen WC, et al. Clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. *Infect Drug Resist* 2021;14:2251–2258
- 142 Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. *Drugs* 2016;76(05):567–588
- 143 Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. *In-vitro* activity of the novel fluorocycline eravacycline against carbapenem non-susceptible *Acinetobacter baumannii*. *Int J Antimicrob Agents* 2018;51(01):62–64
- 144 Van Hise N, Petrak RM, Skorodin NC, et al. A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline. *Infect Dis Ther* 2020;9(04):1017–1028
- 145 Alosaimy S, Abdul-Mutakabbir JC, Kebriai R, Jorgensen SCJ, Rybak MJ. Evaluation of eravacycline: a novel fluorocycline. *Pharmacotherapy* 2020;40(03):221–238
- 146 Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. *Antimicrob Agents Chemother* 2014;58(04):2113–2118
- 147 Dale GE, Halabi A, Petersen-Sylla M, Wach A, Zwingelstein C. Pharmacokinetics, tolerability, and safety of murepavadin, a novel antipseudomonal antibiotic, in subjects with mild, moderate, or severe renal function impairment. *Antimicrob Agents Chemother* 2018;62(09):e00490–18
- 148 Díez-Aguilar M, Hernández-García M, Morosini MI, et al. Murepavadin antimicrobial activity against and resistance development in cystic fibrosis *Pseudomonas aeruginosa* isolates. *J Antimicrob Chemother* 2021;76(04):984–992
- 149 Ekkelenkamp MB, Cantón R, Díez-Aguilar M, et al. Susceptibility of *Pseudomonas aeruginosa* recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics. *Antimicrob Agents Chemother* 2020;64(02):e01541–19
- 150 Locher HHCP, Brun S, Morrissey I, et al. Poster P1836. Activity of Murepavadin against Colistin-Resistant *Pseudomonas aeruginosa* Clinical Isolates 29th ECCMID. Amsterdam, The Netherlands 2019
- 151 Melchers MJ, Teague J, Warn P, et al. Pharmacokinetics and pharmacodynamics of murepavadin in neutropenic mouse models. *Antimicrob Agents Chemother* 2019;63(03):e01699–18
- 152 Armaganidis A, Frantzeskaki F, Diakaki C, et al. Poster 1308. Pharmacokinetic and efficacy analysis of murepavadin (POL7080) coadministered with standard-of-care (SoC) in a phase II study in patients with ventilator-associated pneumonia (VAP) due to suspected or documented *Pseudomonas aeruginosa* infection. 27th Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria; 2017
- 153 Andrews J, Honeybourne D, Ashby J, et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. *J Antimicrob Chemother* 2007;60(03):677–680
- 154 Huang DB, Dryden M. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. *Future Microbiol* 2018;13:957–969
- 155 Huang DB, File TM Jr, Torres A, et al. A Phase II randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin for the treatment of nosocomial pneumonia suspected or confirmed to be due to gram-positive pathogens. *Clin Ther* 2017;39(08):1706–1718
- 156 Monsel A, Torres A, Zhu Y, Pugin J, Rello J, Rouby J. European Investigators Network for Nebulized Antibiotics in Ventilator-associated Pneumonia (ENAVAP) Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. *Curr Opin Infect Dis* 2021;34(02):156–168
- 157 Bassetti M, Vena A, Russo A, Peghin M. Inhaled liposomal antimicrobial delivery in lung infections. *Drugs* 2020;80(13):1309–1318

- 158 Serisier DJ, Bilton D, De Soyza A, et al; ORBIT-2 Investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. *Thorax* 2013;68(09):812–817
- 159 Haworth CS, Bilton D, Chalmers JD, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with *Pseudomonas aeruginosa* (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. *Lancet Respir Med* 2019;7(03):213–226
- 160 Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. *Chest* 2017;151(06):1239–1246
- 161 Kaku N, Morinaga Y, Takeda K, et al. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2017;72(04):1123–1128
- 162 Hamada Y, Suematsu H, Hirai J, Yamagishi Y, Mikamo H. [Evaluation of six cases of arbekacin inhalation for pneumonia]. *Jpn J Antibiot* 2014;67(04):233–239
- 163 Wang J, Kutter JP, Mu H, Moodley A, Yang M. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria. *Int J Pharm* 2020;590:119877
- 164 Li M, Chang RYK, Lin Y, Morales S, Kutter E, Chan HK. Phage cocktail powder for *Pseudomonas aeruginosa* respiratory infections. *Int J Pharm* 2021;596:120200
- 165 Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan HK. Synergy of nebulized phage PEV20 and ciprofloxacin combination against *Pseudomonas aeruginosa*. *Int J Pharm* 2018;551(1-2):158–165
- 166 Lin Y, Quan D, Chang RYK, et al. Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation - a proof-of-principle study in a *P. aeruginosa* lung infection model. *Eur J Pharm Biopharm* 2021;158:166–171
- 167 Guillon A, Pardessus J, L'Hostis G, et al. Inhaled bacteriophage therapy in a porcine model of pneumonia caused by *Pseudomonas aeruginosa* during mechanical ventilation. *Br J Pharmacol* 2021;178(18):3829–3842
- 168 Wang Y, Khanal D, Chang RYK, et al. Can bacteriophage endolysins be nebulised for inhalation delivery against *Streptococcus pneumoniae*? *Int J Pharm* 2020;591:119982